Cantuzumab mertansine
Product Specifications
UNSPSC Description
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].
Target Antigen
Antibody-Drug Conjugates (ADCs); Microtubule/Tubulin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cantuzumab-mertansine.html
Purity
96.02
Solubility
10 mM in DMSO
Smiles
[Cantuzumab mertansine]
Molecular Weight
150000 (average)
References & Citations
[1]Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10(13):4363-8.|[2]Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21(2):211-22.
Shipping Conditions
Room temperature
Storage Conditions
-80°C, protect from light
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99492/Cantuzumab-mertansine-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99492/
Clinical Information
No Development Reported
CAS Number
400010-39-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
